

Project Title	Funding	Strategic Plan Objective	Institution
Developing treatment, treatment validation, and treatment scope in the setting of an autism clinical trial	\$0	Q4.L.A	University of Medicine & Dentistry of New Jersey
Intranasal oxytocin for the treatment of children and adolescents with autism spectrum disorders (ASD)	\$0	Q4.S.C	Holland Bloorview Kids Rehabilitation Hospital
Treatment of sleep problems in children with autism spectrum disorder with melatonin: A double-blind, placebo-controlled study	\$0	Q4.S.A	Baylor College of Medicine
Developing treatment, treatment validation, and treatment scope in the setting of an autism clinical trial	\$0	Q4.L.A	University of Medicine & Dentistry of New Jersey - Robert Wood Johnson Medical School
Clinical Trials Network	\$0	Q4.L.A	Autism Speaks (AS)
Developing treatment, treatment validation, and treatment scope in the setting of an autism clinical trial	\$0	Q4.L.A	University of Medicine & Dentistry of New Jersey - Robert Wood Johnson Medical School
Clinical trial: Treatment of sleep problems in children with autism spectrum disorder with melatonin: A double-blind, placebo-controlled study	\$16,227	Q4.S.A	Baylor College of Medicine
Leadership Education in Neurodevelopmental Disabilities	\$26,000	Q4.Other	University of Pennsylvania
Outcome Measures for Clinical Trials with Individuals with ASD: Challenges and Opportunities	\$26,000	Q4.S.E	N/A
Randomized phase 2 trial of RAD001 (an mTOR inhibitor) in patients with tuberous sclerosis complex	\$65,000	Q4.L.A	Boston Children's Hospital
Association of cholinergic system dysfunction with autistic behavior in fragile X syndrome: Pharmacologic and imaging probes	\$91,292	Q4.L.A	Stanford University
A multi-site double-blind placebo-controlled trial of memantine vs. placebo in children with autism	\$97,238	Q4.L.A	Holland Bloorview Kids Rehabilitation Hospital
Mirtazapine treatment of anxiety in children and adolescents with pervasive developmental disorders	\$99,993	Q4.L.C	Indiana University
Pharmacotherapy of pervasive developmental disorders	\$184,540	Q4.L.C	Indiana University-Purdue University Indianapolis
Predictors of effects of propranolol on language & connectivity in autism	\$188,378	Q4.S.F	University of Missouri
Building a selective inhibitory control tone in autism: An rTMS study	\$219,780	Q4.Other	University of Louisville
ACE Center: Understanding repetitive behavior in autism	\$257,803	Q4.L.A	University of California, Los Angeles
1/3-Atomoxetine placebo and parent training in autism	\$269,971	Q4.S.F	University of Pittsburgh
3/3-Atomoxetine placebo and parent training in autism	\$274,428	Q4.S.F	University of Rochester
Controlled trial of sertraline in young children with Fragile X Syndrome	\$285,177	Q4.L.A	University of California, Davis
2/4-RUPP Autism Network: Guanfacine for the treatment of hyperactivity in PDD	\$311,729	Q4.L.C	Seattle Children's Hospital
1/4-RUPP Autism Network: Guanfacine for the treatment of hyperactivity in PDD	\$337,175	Q4.L.C	Indiana University-Purdue University Indianapolis
Trial of a glutamate antagonist in the treatment of OCD and autistic disorders	\$352,969	Q4.L.A	National Institutes of Health

Project Title	Funding	Strategic Plan Objective	Institution
2/3-Atomoxetine placebo and parent training in autism	\$356,865	Q4.S.F	The Ohio State University
Targeted pharmacologic interventions for autism	\$363,488	Q4.L.C	Indiana University-Purdue University Indianapolis
ACE Center: The pharmacogenetics of treatment for insistence sameness in autism	\$378,379	Q4.L.A	University of Illinois at Chicago
3/4-RUPP Autism Network: Guanfacine for the treatment of hyperactivity in PDD	\$393,205	Q4.L.C	University of California, Los Angeles
4/4-RUPP Autism Network: Guanfacine for the treatment of hyperactivity in PDD	\$556,007	Q4.L.C	Yale University
Metabolic signature of antipsychotics used in the treatment of autism	\$588,750	Q4.L.C	University of Cincinnati
Biomarkers in Autism of Aripiprazole and Risperidone Treatment (BAART)	\$651,465	Q4.S.F	Medical University of South Carolina
A randomized, controlled trial of intranasal oxytocin as an adjunct to behavioral therapy for autism spectrum disorder	\$1,159,063	Q4.S.C	Massachusetts General Hospital
ACE Network: Early pharmacotherapy guided by biomarkers in autism	\$1,498,245	Q4.S.F	Wayne State University
Autism Intervention Research Network on Physical Health (AIR-P network)	\$1,797,880	Q4.S.A	Massachusetts General Hospital

